National Action Plan on AMR 2.0 Launched

NAP-AMR 2.0 Launch: Addressing India’s Escalating Antimicrobial Resistance Crisis

On November 19, 2025, the Union Minister for Health and Family Welfare publicly unveiled the National Action Plan for Antimicrobial Resistance (NAP-AMR 2.0), spanning 2025–2029. Key updates included the integration of 20 ministries under the expanded One Health framework and dedicated, time-bound funding allocations. With India carrying the world’s highest burden of multidrug-resistant organisms—80% of patients—this initiative was not merely overdue; it was imperative. However, whether the framework can disrupt entrenched systemic challenges remains an unresolved question.

Institutional Structure: A Multisectoral Framework

The institutional apparatus underpinning NAP-AMR 2.0 demonstrates expanded ambition yet carries the weight of inter-agency complexity. As envisaged, over 20 ministries—including those governing agriculture, pharmaceuticals, and animal husbandry—will coordinate efforts under the umbrella of the Ministry of Health and Family Welfare (MoHFW). This is aligned with the One Health approach that consolidates human, animal, and environmental health systems into an integrated response. Hailing from the foundational 2017 National Action Plan on AMR (NAP-AMR 1.0), lessons learned include gaps in surveillance and laboratory capacity, which the new iteration seeks to rectify.

Notably, NAP-AMR 2.0 incorporates dedicated budgetary provisions, which had been conspicuously absent in its predecessor. As revealed during the launch, ₹2,500 crore has been earmarked for targeted interventions over the next four years. A significant share will prioritize strengthening laboratory networks, promoting antimicrobial stewardship, and regulating non-prescription antibiotic sales. Conceptually robust, the plan compartmentalizes objectives into actionable timelines, including state-level implementation frameworks—a welcome structural addition.

The Scale of India's AMR Challenge: Data and Gaps

The sobering statistics on AMR in India reveal the enormity of the task. In 2019 alone, India contributed 297,000 AMR-related deaths, a figure projected to climb to 2 million annually by 2050. This does not merely represent a public health crisis but also an economic threat, with AMR’s impact estimated to reduce India’s GDP by 2–5% due to diminished labor productivity. Yet, headline numbers often conceal more granular vulnerabilities.

The irony lies in the scope of antibiotic misuse—a pattern both symptomatic and causal. Rural areas, where OTC antibiotic sales are rampant despite legal prohibitions under the Drugs and Cosmetics Act, 1940, remain starkly underserved by surveillance systems. Moreover, the pharmaceutical industry’s role in AMR escalation, through effluent discharge into the environment, continues unchecked. As noted, India hosts one of the largest pharmaceutical manufacturing hubs globally, yet regulatory oversight remains fragmented at best.

Additionally, while the ICMR’s Antibiotic Stewardship Programs (ASPs) are commendable, they reach only tertiary hospitals in major urban centers. Smaller facilities, rural clinics, and informal healthcare providers—a significant segment catering to the poorest—remain outside the fold. These structural exclusions require acknowledgment, not glossing over, within action plans.

Structural Weaknesses: Bureaucratic Coordination and Financial Viability

A principal point of institutional friction is apparent in the inter-ministerial coordination demanded by the One Health framework. Overhauling policies across animal husbandry, agriculture, fisheries, and healthcare is inherently complex. Case in point: control over antibiotic use in livestock—a key driver of AMR—spans state-level veterinary departments and private-sector agribusinesses. These entities operate within semi-regulated spaces, further complicating coherent policy enforcement. Fragmentation risks diluting accountability.

Budgetary adequacy is another latent concern. While ₹2,500 crore is earmarked, history indicates that allocation alone is insufficient when expenditures remain low. Under NAP-AMR 1.0, for instance, only 43% of allocated funds reached their intended targets, often due to bureaucratic delays and lack of capacity enhancement in smaller states.

Lessons from Sweden: A Case Study in Stewardship

India might find a useful comparator in Sweden, which operates under a cutting-edge AMR containment framework. Unlike India, Sweden mandates stringent prescription controls and tracks antibiotic resistance through a centralized microbial surveillance system that ensures nationwide coverage. Notably, its antibiotic consumption is among Europe’s lowest, falling below 10 daily doses per 1,000 inhabitants. Sweden’s robust countermeasures in agricultural antibiotics—mandatory inspections, capped usage thresholds, and fines for violations—underline a regulatory commitment missing in India’s fragmented state implementation models.

While mimicking Sweden’s centralized surveillance systems may be impractical in India’s federal setup, targeted adoption of regulatory mechanisms, such as tighter restrictions on pharmaceutical effluents, could serve as achievable interim measures.

Forward Momentum or Institutional Stagnation?

For NAP-AMR 2.0 to succeed, three immediate priorities stand out. First, the surveillance network must expand beyond India’s metropolitan centers into hard-to-reach rural pockets. Second, regulatory enforcement must tackle the erratic implementation of restrictions under the Drugs and Cosmetics Act concerning OTC antibiotic sales. Lastly, public awareness campaigns need to move beyond episodic advertisements and into sustained community-led efforts.

Yet, success metrics remain elusive. Will AMR-related mortality reduce? Will state-level implementation timelines hold? The answers lie in measurable outcomes and accountability mechanisms—not grand launch announcements. The structural limitations of India’s federal health architecture must be an active concern, not a footnote.

Prelims Practice Questions

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions